Translation of novel genetic biomarkers of various malignancies into clinical practice
Shao Jian-Yong's Laboratory

Personalized Medicine is quickly becoming a mainstay in the medical development. However, Personalized Medicine in Oncology is still at a nearly stage. To improve the prevention, diagnosis and treatment of tumor, we devote ourselves to the translation of novel genetic biomarkers of various malignancies into clinical practice. Our laboratory also maintains a specific interest in clinical and basic research about pathogenesis, molecular genotyping and personalized treatment of nasopharyngeal carcinoma. We developed a eight-signature classifier for prediction of nasopharyngeal carcinoma prognosis from a series of candidate biomarkers by SVM algorithm, including sex and seven genes, Epstein-Barr virus latency membrane protein 1, CD147, caveolin-1, phospho-P70S6 kinase, MMP11, survivin,and SPARC (Journal of Clinical Oncology 2011, 29: 4516-1525). And we identified profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing and quantitative realtime-PCR (Clinical Chemistry 2014, 60: 773-782). The study of miRNAs in breast cancer led to discovery of up-regulated miR-21 and down-regulated miR-125b in breast cancer that correlated well with patient’s prognosis and metastasis, which in turn has served as the basis for the development of targeted therapy for breast cancer(RNA. 2008 14: 2348-2360.; Cancer Res.,2011, Breast Cancer Research,2011; Breast Cancer Research 2011;13(1):R2; Cancer Res. 2011;71(10):3552-62).  Through collaborative research studies combining basic, translational, and clinical approaches we are seeking to understand triggers of nasopharyngeal carcinoma progression and develop better tools to monitor responses to targeted therapy of various cancers especially for nasopharyngeal carcinoma, lung cancer, breast cancer, stomach cancer and colorectal cancer. Our research group started researching for miRNA in cancers in the early stage, and our studies are widely accepted and have high international influence.

Contact Information
Administrative Offices

Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, 21 Qing Cai Gang Road, Guangzhou, 510060, People’s Republic of China;
Tel: +86 020 8734 5599;
Fax: +86-020-87345599;
Email : 

Lab Members

Current Lab Members

Shao Jian-yong,MD., PhD., Principal Investigator

-  He Cai-Yun, PhD., Research Assistant

-  Cen Wen-Jian, technician

-  Ph.D and postgraduate students: Wang Fang, Fu Sha, Zhu Hao-Tu, Xu Cui-Wei, Xie Guo-Feng, Liu Rong-bin, FengYan-Fen, Abdulbaqi, and Wang Jing  



YaoKai-Tai, MD., PhD., Southern Medical University

Cao Ya, MD.,PhD., Xiangya Medical College of South Central University

Gao Li andZhang Zhi-Hui, MD., PhD., Cancer Hospital, Chinese Academy of Medical Sciences

ZhengYu-Min, MD., PhD., Wuzhou Red Cross Hospital

Labs and Equipment

ShaoJian-Yong Laboratory is located in the Department of Molecular diagnostics at Sun Yat-sen University Cancer Center (SYSUCC). It is an outstanding environment for basic science and translational research. There is a strong core of PhD, graduate and undergraduate students that contribute to the research. Prof. Shao Jian-Yong serves as the leader of our research group, who successively presides over or is mainly responsible for two projects of National Major Fundamental Research Program of China (973 and 863 programs) and 16 projects of Natural Science Foundation of China or Science Project of Guangdong Province, in addition to which he joins in 15 other research projects in China. The research in the Department is also greatly enhanced by SYSUCC.

GMP Certified Workshops


GMP (Good Manufacturing Practice) certified workshops are separately used for reagent preparation, nuclear acid extraction, PCR amplification and PCR product electrophoresis.

Specialized Labs


We set up several specialized labs for nucleic acid amplification, Sanger sequencing, Next-Generation sequencing, genotyping, FISH(fluorescence in situ hybridization), and molecular biology.

 Sequencing and Microarray Facility

The Sequencing and Microarray Facility provides our research group with reliable nucleic acid analysis. There are internationally advanced gene-testing systems including Cobas z480 and ABI7500 realtime-PCR amplifier, ABI3500XL genetic analyzer, W2600SPR biosense chip analyzer, Sequenom MassARRAY platforms,and Next-Generation sequencing system. The goal of our laboratory is to establish an advanced international testing center that adapt to high-throughput, moderate-throughput or low-throughput test for genetics and genomics research.

Microscopy Facility

The laboratory maintains a modern Microscopy Core with multiple platforms for live imaging, fluorescent imaging, bright field microscopy, etc. Imaging is supported by numerous software programs for processing and analyzing data sets.

Molecular Biological Facility

The primary goal of these molecular biological facilities is to offer conventional and molecular cytogenetic services for genotyping, analysis of gene expression,cell culture and so on.


Research Interests

The post-genomic era has provided unprecedented opportunity to examine the complex role of aberrant gene expression and regulation in the development and progression of cancer. The goal of our work is to develop molecular classification and molecular target for cancers by using various molecular biological methods. We believe that a clearer understanding of these biomarkers will translate into advancements in personalized diagnosis and treatment of cancer.

Chromosome 7 Disomy Predicts Resistance to Cetuximab inKRAS Wild-type Metastatic Colorectal Cancer Patients

Li,Y.H., et al., Clin Cancer Res, 2011.17(2): p. 382-90.PMID: 20884623

FISH detection of EGFR copy and chromosome 7 disomy.A,EGFR gene focal amplification in tumor cells. B, increase in EGFR gene copy number and polysomy of chromosome 7. C, homogenous of EGFR gene copy number with a homogeneous chromosome 7 Trisomy. D, no EGFR gene copy number and chromosome 7 disomy alteration pattern.

Metastatic colorectal cancer patients with low epidermal growth factor receptor (EGFR)gene copy number are unlikely to respond to anti-EGFR monoclonal antibody (mAb)treatment. Our results showed firstly that it may be feasible to consider EGFR FISH pattern of chromosome 7 disomy as a negative predictive factor for cetuximab response in KRAS wild-type metastatic colorectal cancer. Together with KRAS mutation, chromosome 7 disomy predicts metastatic colorectal cancer patients will not respond to cetuximab.

Eight-Signature Classifier for Prediction of Nasopharyngeal Carcinoma Survival

Wang, H.Y., et al., J Clin Oncol, 2011.29(34): p. 4516-25.

Receiver operating characteristic (ROC) curves and Kaplan-Meier survival estimates of evaluated patients with nasopharnyngeal carcinoma (NPC) from both training and validation cohorts. ROC curves for molecular markers, age at diagnosis, WHO histologic classification, sex, clinical stage, and NPC–support vector machine (SVM) classifier as predictors of death as result of NPC within 5 years in (A) training and (B) validation cohorts. Kaplan-Meier survival estimates for low- and high-risk patients with NPC as defined by NPC-SVM classifier. Disease-specific survival curves of evaluated patients in (C) training and (D) validation cohorts.

Currently, nasopharyngeal carcinoma (NPC) prognosis evaluation is based primarily on the TNM staging system. We used support vector machine (SVM) –based methods to develop a prognostic classifier for NPC (NPC-SVM classifier) from 18 biomarkers. The NPC-SVM classifier integrated patient sex and the protein expression level of seven genes, including Epstein-Barr virus latency membrane protein 1, CD147, caveolin-1, phospho-P70S6 kinase, matrix metalloproteinase 11, survivin, and secreted protein acidic and rich in cysteine. This classifier distinguished patients with NPC into low- and high-risk groups with significant differences in 5-year DSS in the evaluated patients and in the validation cohort. The newly developed NPC-SVM classifier based on tumor-associated biomarkers will facilitate patient counseling and individualize management of patients with NPC.

miR-125bis Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer

Zhang, Y.,et al., Cancer Res, 2011.71(10): p. 3552-62.

ETS1 is a direct target of miR-125b and knockdown of ETS1 suppresses cell growth, proliferation, and induces G1 cell-cycle arrest.

The miR-125b is dysregulated in various human cancers but its underlying mechanisms of action are poorly understood. We report that miR-125b is down regulated in invasive breast cancers where it predicts poor patient survival. Hypermethylation of the miR-125b promoter partially accounted for reduction of miR-125b expression in human breast cancer. Ectopic restoration of miR-125b expression in breast cancer cells suppressed proliferation, induced G1 cell-cycle arrest in vitro, and inhibited tumorigenesis in vivo. We identified the ETS1 gene as a novel direct target of miR-125b. siRNA-mediated ETS1 knockdown phenocopied the effect of miR-125b in breast cell lines and ETS1 overexpression in invasive breast cancer tissues also correlated with poor patient prognosis. Our findings point to an important role for miR-125b in the molecular etiology of invasive breast cancer, and they suggest miR-125b as a potential theranostic tool in this disease.

Active Research Projects

Funding Sources

Project Name

Project Number

863 project

Molecular Genotyping and Personalized Diagnosis and Treatment of Major Diseases


973 project

Molecular Mechanism of Viral Latent Infection



Molecular Genotyping and Personalized Diagnosis and Treatment of Major Diseases


the National Science Foundation

Study on the Mechanism of miR-30 in Regulation Invasion and Metastasis of Nasopharyngeal Carcinoma


the National Science Foundation

The Molecular Mechanism and Clinical Significance of miR-29a regulating the Epithelial Mesenchymal Transition in Nasopharyngeal Carcinoma


 Lectures and Seminars

Academic reports made by Prof. Shao Jian-Yong at important domestic and international conferences in 2013




NPC Histological  Diagnosis for NIH GrantRo1






















第九届中国病理主任会与Journal of pathology联合会议暨分子病理与病理学术研讨会


Research forums in primary medical units


Country-level continuing education projects for the Application of Molecular Pathology Techniques in Oncology Treatment


 News & Awards



Second Prize of the State Natural Science Award and First Reward of the Science and Technology Progress in Guangdong Province



1.    Wang HY, Yan LX, Shao Q, Fu S, Zhang ZC, Ye W, Zeng YX, Shao JY*.Profiling Plasma MicroRNA in Nasopharyngeal Carcinoma with Deep Sequencing.Clin Chem. 2014 60: 773-782 (IF=7.149)

2.    Fu S,Wang F,Shao Q,Zhang X,Duan LP,Zhang X,Zhang L,Shao JY*.Detection of EML4-ALK FusionGene in Chinese Non-Small Cell Lung Cancer by Using a Sensitive QuantitativeReal-Time Reverse Transcriptase PCR Techniqu.Diagn Mol Pathol.2014 Jan 30.(IF=1.861)

3.    Zhang ZC,Li YY,Wang HY,Fu S,Wang XP,Zeng MS,Zeng YX,Shao JY*.Knockdown of miR-214Promotes Apoptosis and Inhibits Cell Proliferation in Nasopharyngeal Carcinoma.PLoS One.2014 21;9(1):e86149.(IF=3.73)

4.    Jia SW,Fu S,Wang F,Shao Q,Huang HB,Shao JY*. ALK gene copy number gainand its clinical significance in hepatocellular carcinoma.World JGastroenterol.2014 Jan 7;20(1):183-92. (IF=2.547)

5.     Zhao ZR. Wang JF. Lin YB. WangF. Fu S. Zhang SL. Su XD. Jiang L. Zhang YG.Shao JY*. Long H..Mutation abundance affects the efficacy of EGFRtyrosine kinase inhibitor readministration in non-small-cell lung cancer withacquired resistance. Med Oncol.2014 Jan;31(1):810. (IF=2.147)

6.    Li YY,Fu S,Wang XP,Wang HY,Zeng MS,Shao JY*. Down-regulation of c9orf86in human breast cancer cells inhibits cell proliferation, invasion and tumorgrowth and correlates with survival of breast cancer patients.PLoS One.2013 Aug 14;8(8):e71764.(IF=3.73)

7.    WangF, FuSShaoQ, Zhou YB,ZhangX,ZhangX,XueC,LinJG,HuangLX, ZhangL,ZhangWM, and ShaoJY*. High EGFR copy numberpredicts benefits from tyrosine kinase inhibitor treatment for non-small celllung cancer patients with wild-type EGFR. J Transl Med. 2013; 11: 90.(IF= 3.459)

8.    Zhang JXCai MBWang XPDuan LPShao QTong ZTLiao DZLi YYHuang MY,Zeng YXShao JY*.Elevated DLL4expression is correlated with VEGF and predicts poor prognosis ofnasopharyngeal carcinoma.Med Oncol. 2013 Mar;30(1):390. (IF= 2.147)

9.    Hu CWei WChen XWoodman CBYao YNicholls JMJoab ISihota SKShao JY,Derkaoui KDAmari AMaloney SLBell AIMurray PGDawson CWYoung LS,Arrand JR.A global view ofthe oncogenic landscape in nasopharyngeal carcinoma: an integrated analysis atthe genetic and expression levels.PLoS One. 2012;7(7):e41055. (IF=3.73)

10. Cai MBHan HQBei JXLiu CCLei JJCui QFeng QSWang HYZhang JXLiang YChen LZKang TBShao JYZeng YX.Expression ofhuman leukocyte antigen G is associated with prognosis in nasopharyngealcarcinoma.Int J Biol Sci. 2012;8(6):891-900. (IF= 3.168)

11. Li XJPeng LXShao JYLu WHZhang JXChen SChen ZYXiang YQBao YN,Zheng FJZeng MSKang TBZeng YXTeh BTQian CN.As anindependent unfavorable prognostic factor, IL-8 promotes metastasis ofnasopharyngeal carcinoma through induction of epithelial-mesenchymal transitionand activation of AKT signaling.Carcinogenesis. 2012 Jul;33(7):1302-9.(IF= 5.635)

12. Cai MBWang XPZhang JXHan HQLiu CCBei JXPeng RJLiang YFeng QS,Wang HYChen LZFu SKang TShao JYZeng YX.Expression ofheat shock protein 70 in nasopharyngeal carcinomas: different expressionpatterns correlate with distinct clinical prognosis.J Transl Med. 2012 May 16;10:96. (IF=3.459)

13. Wang HY, Li YY, Shao Q, Hou JH, Wang F, Cai MB, Zeng YX, Shao JY*.Secreted protein acidic and rich in cysteine (SPARC) is associated withnasopharyngeal carcinoma metastasis and poor prognosis.J Transl Med.2012;10(1):27.(IF= 3.459)

14.  Du ZM,Kou CW, Hu CF, Chen J, Wang HY, Yan LX, Ernberg I, Zeng YX, and Shao JY*.Clinical Significance of Elevated Spleen Tyrosine Kinase Expression inNasopharyngeal Carcinoma. Head and Neck,2012.doi: 10.1002/hed.21953. (IF= 2.833)

15.  ZhangLJ, Cai L, Li Z, Wang WP, Guo K, Shao JY, Wang JY, Yu H, Rong TH. Relationshipbetween epidermal growth factor receptor gene mutation and copy number inChinese patients with non-small cell lung cancer. Chin J Cancer. 2012. Hai-YunWang, Bing-Yu Sun, Zhi-Hua Zhu, Ellen T. Chang, Ka-Fai To, Jacqueline S.G.Hwang, Hao Jiang,Michael Koon-Ming Kam, Gang Chen, Shie-Lee Cheah, Ming Lee,Zhi-Wei Liu, Jing Chen, Jia-Xing Zhang,Hui-Zhong Zhang, Jie-Hua He, Fa-LongChen, Xiao-Dong Zhu, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu,Qiong Shao, Man-BoCai, Zi-Ming Du, Li-Xu Yan, Chun-Fang Hu, Ho-Keung Ng, Joseph T.S. Wee,Chao-NanQian, Qing Liu, Ingemar Ernberg, Weimin Ye, Hans-Olov Adami, Anthony T. Chan,Yi-Xin Zeng,and Shao JY*. An Eight-signature Classifier for Prediction ofNasopharnyngeal Carcinoma Survival. Journal of Clinical Oncology, 2011; 29(34):4516-4525. (IF=18.083)

16.  Du ZM,Hu LF, Wang HY, Yan LX, Zeng YX, Shao JY*, Ernberg I. Upregulation of MiR-155in Nasopharyngeal Carcinoma is Partly Driven by LMP1 and LMP2A andDownregulates a Negative Prognostic Marker JMJD1A. PLoS One. 2011; 6(4):e19137.(IF= 3.73)

17.  ZhangY, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS,Huang W, Zeng YX, Shao JY*. miR-125b is Methylated and Functions as A TumorSuppressor by Regulating the ETS1 proto-oncogene in Human Invasive BreastCancer. Cancer Res. 2011;71(10):3552-62. (IF= 8.65)

18.  Li XJ,Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WQ, Zhang ZF, Petillo D,Lin Q, Bao YN, Zheng FJ, Claramae SC, N Gopalakrishna lyer, Kang BT, Zeng YX,Khee CS, Jeffrey MT, Teh BT, Qian CN. Serglycin Is a Theranostic Target inNasopharyngeal Carcinoma that Promotes Metastasis. Cancer Res.2011;71(8):3162-3172. (IF= 8.65)

19.  An X,Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH. Plasma Epstein-Barrvirus DNA level strongly predicts survival in metastatic/recurrentnasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 2011;117(16):    3750-7. (IF= 5.201)

20.  YanLX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, ZengYX, Shao JY*. Knockdown of miR-21 in human breast cancer cell lines inhibitsproliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res.2011;13(1):R2. (IF= 5.872)

21. Li YH, Wang F, Shen L, Deng YM, Shao Q,Feng F, An X, Wang FH, Wang ZQ, Xu RH, Shao JY*. EGFR FISH Pattern ofChromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-typeMetastatic Colorectal Cancer Patients. Clin. Cancer Res. 2011;17(2):382-90.(IF= 7.837)

22.  ShaoJY*, Cao Y, Miao XP, Huang MY, Deng L, Hao JJ, Liang XM, Hu LF, Ingemar E, LinDX, Zeng YX. A single nucleotide polymorphism in the Matrix Metalloproteinase-2promoter is closely associated with high risk of nasopharyngeal carcinoma inCantonese from southern China. Chin. J. Cancer, 2011;30(9):620-6. (IF= 0.448)

23.  Cao Y,Miao XP, Zeng YX, Lin DX, Shao JY*. Association between genetic polymorphismsof CYP2A13, CYP2A6 and risk of nasopharyngeal carcinoma in southern Chinesepopulation. Cancer Biology, 2011;1(1). (IF= 3.287)

24.  ZhangY, Hu CF, Chen J, Yan LX, Zeng YX, Shao JY*. LATS2 is de-methylated andoverexpressed in nasopharyngeal carcinoma and predicts poor prognosis. BMCCancer. 2010;10:538. (IF= 3.333)

25. Cao Y, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, Shao JY*. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol. Carcinog. 2010;49(11):944-50. (IF= 4.269)

26. Cao Y, Miao XP, Huang MY, Deng L, LiangXM, Lin DX, Zeng YX, Shao JY*. Polymorphisms of methylenetetrahydrofolatereductase are associated with a high risk of nasopharyngeal carcinoma in asmoking population from southern China. Mol. Carcinog. 2010;49(11):928-34. (IF=4.269)

27. Kong QL, Hu LJ, Cao JY, Huang YJ, XuLH, Liang Y, Xiong D, Guan S, Guo BH, Mai HQ, Chen QY, Zhang X, Li MZ, Shao JY,Qian CN, Xia YF, Song LB, Zeng YX, Zeng MS.Epstein-Barr virus-encoded LMP2Ainduces an epithelial-mesenchymal transition and increases the number of sidepopulation stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog.2010; 6(6):e1000940. (IF= 8.136)

28. Valentine R,Dawson CW,Hu C,Shah KM,Owen TJ,Date KL,Maia SP,Shao J,Arrand JR,Young LS,O'Neil JD.Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway incarcinoma cells by inhibiting IKK phosphorylation.Mol Cancer.2010;9:1. (IF= 5.134)

29.  Guo BH, Zhang X, Zhang HZ, LinHL, Feng Y, Shao JY, Huang WL, Kung HF, Zeng MS. Low expression of Mel-18predicts poor prognosis in patients with breast cancer. Ann Oncol.2010;21(12):2361-9. (IF= 7.384)

30.  Chen J, Hu CF, Hou JH, Shao Q,Yan LX, Zhu XF, Zeng YX and Shao JY*. Epstein-Barr Virus Encoded LatentMembrane Protein 1 Regulates mTOR Signaling Pathway Genes Which Predict PoorPrognosis of Nasopharyngeal Carcinoma. J. Transl. Med. 2010;8:30. (IF= 3.459)

31. Du ZM,Hu CF,Shao Q,Huang MY,Kou CW,Zhu XF,Zeng YX,Shao JY*.Upregulation ofcaveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cellmigration and correlated with poor prognosis of the patients.Int. J. Cancer.2009; 125(8):1832-41. (IF=6.198)

32.  Yan LX, Huang XF, Shao Q,Huang MY, Deng L, Wu QL, Zeng YX, Shao JY*. MicroRNA miR-21 Overexpression inHuman Breast Cancer is Associated with Advanced Clinical Stage, Lymph NodeMetastasis and Patient Poor Prognosis. RNA. 2008 14: 2348-2360. (IF= 5.088)

33.  Pang LJ, Shao JY*, Liang XM,Xia YF, Zeng YX. Mitochondrial DNA somatic mutations are frequent innasopharyngeal carcinoma. Cancer Biol. Ther. 2008, 7(2):198-207. (IF= 3.287)

34.  Li YH, Hu CF, Shao Q, HuangMY, Hou JH, Xie D, Zeng YX, Shao JY*. Elevated Expressions of Survivin and VEGFProtein Are Strong Independent Predictors of Survival in AdvancedNasopharyngeal Carcinoma. J Transl Med. 2008, 3;6(1):1. (IF= 3.459)

35. Zhu ZH,Sun BY,Ma Y,Shao JY,Long H,Zhang X,Fu JH,Zhang LJ,Su XD,Wu QL,Ling P,Chen M,Xie ZM,Hu Y,Rong TH.Threeimmunomarker support vector machines-based prognostic classifiers for stage IBnon-small-cell lung cancer.J Clin Oncol.2009; 27(7): 1091-9. (IF=18.038)

36. Cheung AK,Lung HL,Hung SC,Law EW,Cheng Y,Yau WL,Bangarusamy DK,Miller LD,Liu ET,Shao JY,Kou CW,Chua D,Zabarovsky ER,Tsao SW,Stanbridge EJ,Lung ML.Functional analysisof a cell cycle-associated, tumor-suppressive gene, protein tyrosinephosphatase receptor type G, in nasopharyngeal carcinoma.Cancer Res.2008;68(19):8137-45. (IF=8.65)

37.  Cao Y, Miao XP, Huang MY, DengL, Hu LF, Ernberg I, Zeng YX, Lin DX, Shao JY*. Polymorphisms of XRCC1 genesand risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer,2006, 6:167. (IF= 3.333)

38. Li Y, Shao JY, Liu RY, Zhou L, Chai LP, Li HL, HanHY, Huang BJ, Zeng MS, Zhu XF, Liu Q, Fu LW, Huang WEvaluation of Long-TermToxicity of Ad/hIFN-gamma, an Adenoviral Vector Encoding the HumanInterferon-gamma Gene, in Nonhuman Primates.Hum Gene Ther.2008;19(8):827-39. (IF=4.019)

39.  Liu MZ, Xie D, Mai SJ, TongZT, Shao JY, Fu YS, Xia WJ, Kung HF, Guan XY, Zeng YX. Overexpression of AIB1in nasopharyngeal carcinomas correlates closely with advanced tumor stage.Am J Clin Pathol.2008;129(5):728-34. (IF=2.881)

40.  Li HL , Li S , Shao JY , LinXB , Cao Y , Jiang WQ , Liu RY , Zhao P , Zhu XF , Zeng MS , Guan ZZ , Huang W.Pharmacokinetic and pharmacodynamic study of intratumoral injection of anadenovirus encoding endostatin in patients with advanced tumors.Gene Ther.2008;15(4):247-56. (IF=4.321)

41.  Song LB; Zeng MS; Liao WT,Zhang Ling, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, HuangWL,Goberdhan PD, Vimia B, Zeng YX. Bmi-1 is a novel molecular marker ofnasopharyngeal carcinoma progression and immortalizes primary humannasopharyngeal epithelial cells. Cancer Res. 2006;6(12):6225-32. (IF= 8.65)

42. Pan ZG, Kashuba VI, Liu XQ, Shao JY, Zhang RH, JiangJH, Guo C, Eugene Z, Ingemar E, Zeng YX.Highfrequency somatic mutations in RASSF1A in nasopharyngeal carcinoma. CancerBiol Ther. 2005;4(10):1116-22. (IF= 3.287)

43.  Pan ZZ, Wan DS, Zhang CQ, ShaoJY, Li LR, Chen G, Zhou ZW, Wang FL. Using p53-immunostained large specimens todetermine the distal intramural spread margin of rectal cancer. World JGastroenterology,2006;12(10):1626-9.(IF= 2.547)

44.  Shao JY,Li YH, Zhang Y, et al. Comparison of Plasma Epstein-Barr Viruses DNA Level and Serum EBV VCA/IgAAntibody Titers in Nasopharyngeal Carcinoma. Cancer, 2004, 100: 1162-1170. (IF=5.201)

45.  Shao JY, Ernberg I, Biberfeld,et al. Immunostaining studies on nasopharyngeal carcinoma: Interaction of tumorcells, lymphocytes and expression of EBV LMP1. Anticancer Research, 2004,24(4):2309-2318. (IF= 1.872)

46. Shao JY,Gao HY,Li YH,Zhang Y,Lu YY,Zeng YX. Quantitative detection ofcommon deletion of mitochondrial DNA in hepatocellular carcinoma andhepatocellular nodular hyperplasia.World JGastroenterol.2004;10(11):1560-4. (IF= 2.547)

47.  Shao JY, Gao HY, Li YH, et al.High frequency of common deletion (4981 bp) in mitochondrial DNA innasopharyngeal carcinoma and its correlation with patient age and clinicalstages. Cancer Biology & Therapy, 2004, 3(12):1270-1274. (IF= 3.287)

48.  Shao JY,Zhang Y, Li YH, et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral bloodcell and tumor tissue in nasopharyngeal carcinoma: correlations with clinicalparameters.  Anticancer Research,2004,24(6):4059-4066. (IF= 1.713)

49.  Shao JY,Li YH, Wu QL, et al. High frequency loss of heterozygosity on the long arm of chromosome 13 and14 in nasopharyngeal carcinoma in Southern China. Chinese Medical Journal,2002, 115(4):571-575. (IF=0.901)

50.  Shao JY,Huang XM, Yu XJ, et al. Loss of Heterozygosity and its correlation with clinical outcome andEpstein-Barr Virus Infection in Nasopharyngeal Carcinoma. Anticancer Research,2001, 21(4): 3021-3030. (IF= 1.713)

51.  Shao JY,Wang HY, Huang XM, et al. Genome-wide allelotype analysis of sporadic primary nasopharyngealcarcinoma from southern China. Int. J Oncology, 2000, 17: 1267-1275. (IF=2.657)

52.  Xiaoming H, Haiqiang M,Manquan D, Jianyong S, Yong S, Kela L, Xiaoman L, Tengbo H. Examinationof nasopharyngeal epithelium with contact endoscopy. Acta Otolaryngol,2001: 121: 95-102. (IF= 1.106)

53.  Guo X, Min HQ, Zeng MS, QianCN, Huang XM, Shao JY, Hou JH. nm23-H1 expression innasopharyngeal carcinoma: correlation with clinical outcomes. Int. J.Cancer, 79(6):596-600, 1998. (IF= 5.007)

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.